Cannabis and Blood Pressure in Hypertensive Older Adults: What the Study Found

A small clinical study of older adults with hypertension reported lower average blood-pressure readings after three months of medical cannabis treatment. That finding is the reason this topic attracts attention—but it does not show that cannabis treats hypertension, prevents cardiovascular disease, or should replace standard care. The study was observational, involved only 26 participants who completed follow-up, and had no untreated comparison group. This article explains what was measured, what the result can and cannot establish, and why medical decisions belong with a qualified clinician.

What did the older-adult study examine?

Abuhasira and colleagues followed patients aged 60 years or older who had hypertension and received a new prescription for medical cannabis. Researchers measured 24-hour ambulatory blood pressure, heart rate, ECG, blood tests and anthropometric measures before treatment and after three months. Twenty-six participants completed the study; their mean age was about 70 years. The authors reported mean reductions of 5.0 mmHg in 24-hour systolic pressure and 4.5 mmHg in diastolic pressure at follow-up. These are group averages observed over the study period, not a guaranteed individual response.

The paper is a prospective observational study, not a randomized controlled trial. Because there was no control group, the findings cannot determine whether cannabis caused the measured changes. Changes in other treatments, routine, health status, measurement conditions or other factors may also contribute. The result is appropriately described as an association observed in this sample—not proof of an antihypertensive effect.

How to interpret the result without overstating it

Ambulatory monitoring records blood pressure over a day and can provide information beyond a single clinic reading. Even so, a before-and-after measurement in a small group cannot establish efficacy or long-term safety. The study’s modest sample, short follow-up and lack of randomization limit generalization to other older adults, cannabis products, doses, routes of administration or clinical settings.

It is also important not to treat “cannabis” as one standardized intervention. Products can differ in cannabinoid composition, potency, route, timing and accompanying ingredients. The study does not establish that CBD alone, a particular cannabinoid, a commercial hemp ingredient or a specific product format produced the observed changes. It also does not provide a basis for selecting a product or dose to manage blood pressure.

Evidence from other older-adult research

Later observational research provides a useful contrast. An analysis of older participants in the Multi-Ethnic Study of Atherosclerosis found no significant association between a history of regular cannabis smoking and measured blood pressure or prevalent hypertension after adjustment. This was a different population and study design, so it does not directly confirm or refute the small treatment cohort. Taken together, the studies illustrate why a single result should not be presented as settled evidence: populations, exposures and methods differ, and observational associations cannot establish cause and effect.

More robust research would need clearly characterized products, appropriate comparison groups, larger and more diverse samples, longer follow-up, prespecified outcomes and careful assessment of interactions and adverse events. Until then, the evidence does not support presenting cannabis as a blood-pressure treatment.

Why caution matters for older adults

Older adults may have multiple health conditions and take several medicines. A clinician or pharmacist can assess potential interactions, changes in alertness or balance, cardiovascular history and other individual factors. A blood-pressure reading that changes after a product is used should not prompt someone to stop, reduce or replace prescribed treatment without medical advice. Anyone with hypertension should continue their agreed monitoring and treatment plan and discuss cannabis use openly with their healthcare professional.

Seek urgent medical assistance for symptoms that may indicate a medical emergency, such as chest pain, fainting, sudden weakness, severe shortness of breath or a sudden severe headache. This article is general educational information, not medical advice, diagnosis or a recommendation to use cannabis.

What the study does not show

• It does not prove cannabis caused the blood-pressure reductions.
• It does not show that cannabis prevents heart attack, stroke or other cardiovascular outcomes.
• It does not identify a specific cannabinoid, dose, route or commercial product as effective.
• It does not establish long-term benefit or safety, or justify changing prescribed hypertension care.

Implications for product and research teams

For researchers, formulators and professional buyers, this paper is a reminder to distinguish a clinical observation from product substantiation. A study of prescribed medical cannabis cannot be used as evidence for an unrelated ingredient or finished formulation without direct supporting data. Product identity, batch specification, cannabinoid profile, analytical methods and intended market all matter when evaluating evidence or planning a research programme.

Pharmabinoid provides B2B cannabinoid sourcing and formulation information. Businesses comparing ingredient formats can review CBD products and CBD vape products, or explore background information in the cannabinoid research hub. These commercial resources are not medical products or evidence that cannabinoids lower blood pressure.

Conclusion: cannabis and blood pressure in hypertensive older adults

The 2021 study reported lower average 24-hour blood-pressure readings after three months among a small group of older adults with hypertension who were prescribed medical cannabis. Its uncontrolled observational design means it cannot establish causation, treatment efficacy or long-term safety. Other older-adult observational data do not show a consistent simple relationship. The responsible conclusion is that this is an interesting research signal requiring stronger study—not evidence that cannabis treats hypertension. People managing blood pressure should consult their healthcare professional before making any change to treatment.

Frequently asked questions

Did the study prove cannabis lowers blood pressure?

No. It found a reduction between baseline and follow-up in a small observational group, but without a control group it cannot show that cannabis caused the change.

Can cannabis replace prescribed blood-pressure medicine?

No. The study did not test cannabis as a replacement for standard treatment. Do not change prescribed medicines without advice from your healthcare professional.

Does the study apply to CBD products sold commercially?

Not automatically. The study concerned prescribed medical cannabis, and its findings cannot be transferred to a different ingredient, formulation, dose or route without relevant evidence.

Where can I read the primary research?

Read the original 24-hour ambulatory blood-pressure study in older adults and the later MESA analysis of cannabis use and blood pressure in older adults.